Compare DexCom, Inc. (DXCM) vs Taskus Inc (TASK) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

TaskUs (TASK) trades at $6.12, up 5.52% over 24 hours, with a bullish technical signal from moving averages. The company reported strong 2025 results with revenue of $1.18B and net income of $102.28M, supported by a recent CFO appointment and positive robotaxi survey. Valuation ratios like P/E of 5.29 and P/S of 0.46 suggest potential undervaluation relative to earnings and sales.

The outlook is positive with a consensus price target of $9.50, implying significant upside. Risks include Q1 2026 earnings miss and projected negative cash flow for 2026. Analyst sentiment is bullish (55% buy ratings), but investors should monitor execution on future earnings and cash flow trends.